BOULDER, Colo., June 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI™ capsules in combination with ...

Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

* Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for revolving line of credit of up to $5 million * Array Biopharma Inc - loan agreement also provides for ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Hi, good morning everybody and thank you for joining us for Day Three, our final day. Here at Annual BofA Merrill Healthcare Conference in Vegas. We are certainly excited to be able to host Array ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

BOSTON (CBS.MW) -- Shares of Array BioPharma jumped 16 percent in after-hours trading on Monday after the small biotech firm said it'll collaborate with Genentech on research into potential new cancer ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

* Point72 Asset Management L.P reports 5.4 percent passive stake in Array Biopharma Inc as of September 11, 2017 - SEC filing‍ Source text: Further company coverage: ...